{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:08:26Z","timestamp":1770822506586,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.leukres.2003.09.001","type":"journal-article","created":{"date-parts":[[2003,11,6]],"date-time":"2003-11-06T01:53:19Z","timestamp":1068083599000},"page":"421-422","source":"Crossref","is-referenced-by-count":17,"title":["Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis"],"prefix":"10.1016","volume":"28","author":[{"given":"Pellegrino","family":"Musto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Sanpaolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Bodenizza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2003.09.001_BIB1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2003.09.001_BIB2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate: a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.09.001_BIB3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.90.2.735","article-title":"Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand","volume":"90","author":"Mitsui","year":"1993","journal-title":"PNAS U.S.A."},{"key":"10.1016\/j.leukres.2003.09.001_BIB4","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-Kit catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"PNAS U.S.A."},{"key":"10.1016\/j.leukres.2003.09.001_BIB5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.20.6.1692","article-title":"Inhibiton of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies","volume":"20","author":"Heinrich","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.09.001_BIB6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI-571 and other KIT kinase inhibitors: kinase with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.09.001_BIB7","first-page":"1115","article-title":"Juxta-membrane mutant V560Gkit is more sensitive to imatinib (STI571) compared with wild-type c-kit, whereas the kinase domain mutant D816Vkit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2003.09.001_BIB8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2003.09.001_BIB9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2003.09.001_BIB10","first-page":"70a","article-title":"Imatinib therapy for systemic mast cell disease","volume":"100","author":"Pardanani","year":"2002","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603003102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603003102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T11:52:46Z","timestamp":1550404366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212603003102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0145212603003102"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2003.09.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}